CytomX Therapeutics Reports Q2 2026 Financial Results

What Happened CytomX Therapeutics, Inc. announced on August 6, 2026 that it reported unaudited financial results for the three and six months ended June 30, 2026. The company furnished a press release titled "CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update" as Exhibit 99.1 to the Form 8-K. The report was signed by CFO Christopher W. Ogden.

Key Details

• Filing date: August 6, 2026 (Form 8-K, Item 2.02: Results of Operations and Financial Condition).
• Reporting period: unaudited results for the three and six months ended June 30, 2026.
• Exhibit provided: Press release (Exhibit 99.1) contains the detailed earnings/quarterly results and business update.
• Signature: Form 8-K signed by Christopher W. Ogden, Chief Financial Officer.

Why It Matters This filing formally notifies investors that CytomX has released its latest quarterly earnings and financial condition update; those details (revenue, expenses, net loss/profit, cash position, and any business updates) will be in the press release and related filings. Investors should review Exhibit 99.1 and subsequent SEC filings for the specific financial figures and commentary to assess the company’s recent performance and cash runway.